HA
Harsh Agarwal
About Harsh Agarwal
Harsh Agarwal has 9 years in corporate governance. Holds Designated Partner and Director roles. Currently with 3 companies, including Global Pathology Llp and Meka Gravure Solutions Private Limited. Formerly with 1 company, such as Excellent Bio Research Solutions Private Limited. Engaged in General Business, Healthcare. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Global Pathology Llp
ACF-8981
|
Designated Partner | 06 Mar 2024 | 2024 | Active |
Meka Gravure Solutions Private Limited
U74999MP2017PTC043336
|
Director | 18 May 2017 | 2017 | Active |
|
Sysmeta Healthineers Private Limited
U21002MP2023PTC065406
|
Director | 23 Apr 2023 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Excellent Bio Research Solutions Private Limited
U73100MP2013PTC031190
|
Director | 01 Mar 2023 | 2013 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Harsh Agarwal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Harsh Agarwal
Harsh Agarwal has 9 years in corporate governance. Holds Designated Partner and Director roles. Currently with 3 companies, including Global Pathology Llp and Meka Gravure Solutions Private Limited. Formerly with 1 company, such as Excellent Bio Research Solutions Private Limited. Engaged in General Business, Healthcare. Contributes to corporate operations.
Harsh Agarwal is associated with 3 companies as Designated Partner and Director.
Harsh Agarwal has expertise in General Business, Healthcare.
Harsh Agarwal has 9 years in corporate governance.